News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amarantus BioSciences, Inc. Licenses Parkinson’s Disease Diagnostic Biomarker Test from Power3 Medical Products (PWRM)



1/23/2012 6:46:14 AM

SUNNYVALE, Calif. & THE WOODLANDS, Texas--(BUSINESS WIRE)--Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein being developed for the treatment of Parkinson’s Disease, today announced an exclusive worldwide license agreement with Power3 Medical Products, Inc. (OTCBB: PWRM) for the NuroPro® Blood Test as it relates to Parkinson’s disease diagnosis. Concurrent with the license, Amarantus has raised $100,000 from a private, foreign investor introduced to the Company by www.tomorrowsbluechips.com.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES